ONWARD Medical Receives Grants to Enhance Parkinson’s Research
Expanding Horizons in Parkinson’s Disease Treatment
ONWARD Medical N.V. is making significant strides in the world of medical technology with a focus on Parkinson’s disease. The company has secured crucial funding aimed at enhancing research into innovative therapies designed to improve mobility and overall quality of life for individuals living with this complex condition.
Support from the Michael J. Fox Foundation
Recently, the Michael J. Fox Foundation for Parkinson’s Research became an essential contributor to ONWARD Medical's efforts. They awarded a $1 million grant to support a clinical feasibility study that will directly benefit 6 participants. This study aims to determine if the ONWARD ARC-IM System can effectively address mobility challenges commonly faced by those with Parkinson's disease.
Addressing Mobility Challenges
Parkinson's disease presents numerous challenges, particularly regarding mobility. Evidence shows that over 90% of patients struggle with issues such as walking and balance, often leading to serious consequences like falls. Traditional treatments often fall short in tackling these mobility concerns, emphasizing the need for more effective therapies. The findings from prior studies, published in reputable journals, highlighted the potential of ONWARD's innovative technology to positively impact these patients.
Funding from the US Department of Defense
ONWARD Medical also received approximately $1.5 million from the US Department of Defense to further its clinical studies. This grant will facilitate research into the ONWARD ARC-IM System's capabilities in addressing blood pressure instability, a prevalent issue for many individuals with Parkinson’s disease.
The Importance of Blood Pressure Management
Studies suggest that around 800,000 individuals in Europe and the US face challenges due to blood pressure fluctuations associated with Parkinson's. The upcoming study aims to enroll participants in the first half of the coming year, expanding the understanding of how ONWARD’s technology can help manage this critical aspect of the disease.
CEO Insights on Technological Advancements
Dave Marver, the CEO of ONWARD Medical, expressed optimism about the prospects of the ONWARD ARC-IM System, emphasizing the recognition earned through these grants from esteemed organizations. He highlighted that the potential applications of this technology might extend beyond just spinal cord injuries, presenting new hope for the approximately 10 million individuals worldwide who live with Parkinson’s disease.
About the ONWARD ARC-IM System
The ARC-IM System is engineered to provide personalized spinal cord stimulation to restore movement and function for those with spinal cord injuries and other related disabilities. It incorporates an advanced neurostimulator, providing targeted electrical impulses that can influence the spinal cord areas responsible for movement.
About ONWARD Medical
ONWARD Medical is a forward-thinking medical technology organization that focuses on therapies designed to restore independence and mobility for people suffering from spinal cord injuries and various movement disabilities. With a robust foundation built on years of research, clinical studies, and collaborations with leading academic institutions, ONWARD has earned multiple Breakthrough Device Designations from the Food and Drug Administration (FDA) for its ARC Therapy solution.
Headquartered in the Netherlands, and with additional locations in Switzerland and the US, the company remains dedicated to innovation in the field of neurostimulation technology. The ARC-EX System has secured commercial clearance for sale in US markets, and ongoing developmental efforts for the implantable ARC-IM System continue.
Frequently Asked Questions
What is the ONWARD ARC-IM System?
The ONWARD ARC-IM System is designed for spinal cord stimulation to restore movement and functionality in individuals with spinal cord injuries and various movement disabilities.
What grants has ONWARD Medical received for Parkinson's research?
ONWARD Medical received a $1 million grant from the Michael J. Fox Foundation and a $1.5 million grant from the US Department of Defense to support studies on mobility and blood pressure issues in Parkinson's patients.
How many participants are involved in the ONWARD studies?
The studies will involve 6 participants for the mobility study funded by the Michael J. Fox Foundation and 5 participants for the blood pressure study supported by the US Department of Defense.
What challenges do Parkinson’s patients face regarding mobility?
More than 90% of Parkinson’s patients struggle with issues like walking and balance, leading to a significant risk of falls and loss of independence.
Where is ONWARD Medical headquartered?
ONWARD Medical is headquartered in the Netherlands, with additional facilities in Switzerland and the United States.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.